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Abstract
Introduction Classification of breast cancers according to the
HER-2 oncogene status is of central importance in the selection
of post-surgical therapies. A decrease in the proportion of HER-
2-positive breast cancer has been suspected, but no data on the
incidence trends at population level have been reported.
Methods We studied the proportion of HER-2-positive breast
cancers by chromogenic in situ hybridization (CISH) in three
cohorts (years 1982 to 1986 (n = 310), 1989 to 1992 (n =
108), and 2004 to 2005 (n = 713)) in the population of the
Pirkanmaa hospital district (approximately 220,000 women).
Cancer incidence rates were age-adjusted to the world
standard population.
Results The proportion of HER-2-positive breast cancer
declined from 21.6% (average in 1982 to 1986) to 13.6%
(average in 2004 to 2005). However, during the same time
period the age-adjusted incidence of all invasive breast cancers
had increased by 40%. These opposite trends balanced each
other and indicated that the incidence of HER-2-positive breast
cancer has remained unchanged (Poisson regression
coefficient for time trend 1.000; 95% CI = 0.989 to 1.012). In
contrast, the incidence of HER-2-negative cancer showed 2%
annual increase (Poisson regression coefficient 1.021, 95% CI
= 1.016 to 1.026). Although HER-2-negative cancers were
more likely to be diagnosed by mammography screening, the
changes were more likely to be explained by etiological risk
factors favoring HER-2-negative (and hormone receptor-
positive) disease such as menopausal hormone therapy.
Conclusions These results document a significant decrease in
the proportion of HER-2-positive breast cancer. However, the
incidence of HER-2-positive cancer at the population level was
found to be unchanged.
Introduction
The human epidermal growth factor receptor-2 (HER-2) proto-
oncogene has been in the focus of cancer research during the
past two decades. It is well established that amplification of
the HER-2 oncogene correlates with poor prognosis of
patients [1]. More importantly, HER-2 oncogene is the molec-
ular target of trastuzumab and lapatinib based therapies that
are widely used in the treatment of HER-2-positive breast can-
cer. Currently all newly diagnosed breast cancers are assayed
for HER-2 oncogene status [2-5]. HER-2-targeted therapies
cause significant amounts of workload and costs, so accurate
information on the incidence of HER-2-positive breast cancer
is required to estimate the resources needed in clinics.
The incidence of HER-2 amplification in population-based
cohorts of breast cancer is not known precisely. As reviewed
by Cardoso and colleagues [6], the proportion of HER-2-pos-
itive tumors and/or overexpression has ranged between 10
and 40% in different studies. The figures are generally higher
in older literature and in studies using immunohistochemical
assays, which are considered to be less specific than assays
based on in situ hybridization. Most studies describe relatively
small cohorts of patients often including defined subtypes
(node-negative, node-positive or in situ cancers). Due to the
prognostic correlations studied, most studies describe patient
populations whose breast cancers have been diagnosed 5 to
20 years earlier. It is well known that the overall incidence ofPage 1 of 6
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ades [7,8]. Yet the time trends in the incidence of HER-2-pos-
itive breast cancer have remained unclear.
As a reference laboratory responsible for HER-2 tumor diag-
nostics, our laboratory has followed up the proportion of HER-
2-positive tumors analyzed as part of our internal quality assur-
ance. In this study we wanted to explore the apparent discrep-
ancy between our current figures for HER-2 positivity (< 15%)
and those previously reported in the literature (20 to 30%)
[9,10]. Direct comparison between the current situation and
the published studies was not possible, because the specifi-
city and sensitivity of the HER-2 assay methods (immunohisto-
chemistry vs. in situ hybridization) are likely to differ. Therefore,
we studied the incidence trends of HER-2-positive breast can-
cer using chromogenic in situ hybridization (CISH) from 1131
samples of breast cancers diagnosed between 1982 and
2005 in a geographically defined hospital district, namely Pir-
kanmaa in Finland.
Materials and methods
The study material consists of three population-based cohorts
of breast cancer patients, diagnosed during the years 1982 to
1986 (n = 310), 1989 to 1992 (n = 108), and 2004 to 2005
(n = 713) in the Pirkanmaa Hospital District, Finland. All
patients in the study had primary invasive breast cancer con-
firmed histopathologically. The patients diagnosed in 1982 to
1986 and 1989 to 1992 were selected randomly from the
Finnish Cancer Registry database [11], which achieves close
to 100% completeness [12]. Axillary lymph node status data
were derived from the Finnish Cancer Registry, which was
used to ascertain the similarity of the cohorts (Table 1). The
cohorts comprised 32.4% and 11.0%, respectively, of all inva-
sive breast cancer patients reported to the Cancer Registry
from the study area. The newest cohort (cancers diagnosed
between January 2004 and December 2005) included all inva-
sive breast cancers submitted for hormone receptor and HER-
2 analysis. This cohort consisted of 91.8% of cases reported
to the Finnish Cancer Registry for this district.
Formalin-fixed and paraffin-embedded tumor samples were
used for this study. Amplification of HER-2 was determined in
all tumors by using CISH as previously described [13,14]. The
cut-off for amplification was set at six gene copies per cell or
the presence of a typical gene copy cluster [13]. The study
was approved by the Ethical Committee at Tampere University
Hospital.
The age-standardized breast cancer incidence was calculated
using the World Health Organization (WHO) standard popu-
lation [11]. Time trends in the proportion and incidence of
HER-2-positive tumors were analyzed by regression methods,
using a generalized linear model with binomial distribution and
logarithmic link function and incidence trendswith Poisson
regression, both in Stata 8.0 (StataCorp, College Station, Tx,
USA). The outcome was a HER-2-positive tumor and the
Table 1
Characteristics of the study cohorts
Patient cohort 
(year of 
primary 
diagnosis)
Female
population*
Number of 
breast
cancers 
diagnosed 
per year**
Number of 
breast cancers 
in the cohort
(n, %)**
Age at 
diagnosis 
(median, 
range)
Proportion of 
axillary lymph 
node negative 
cancers
Proportion of 
estrogen 
receptor-
positive 
cancers
Proportion of 
progesterone 
receptor-
positive cancers
1982 to 1986
population-
based**
215,639 191 957 63 (27 to 92) 53.1% NA NA
studied cohort 310 (32.4%) 59 (30 to 88) 56.6% 59.4% 69.7%
1989 to 1992
population-
based**,***
220,257 246 985 60 (28 to 92) 58.9% 72.0% 63.0%
studied cohort 108 (11.0%) 64 (34 to 88) 65.2% 77.9% 55.9%
2004 to 2005
population-
based**
231,000 389 777 NA NA NA NA
studied cohort 713 (91.8%) 60 (25 to 94) 56.3% 89.8%**** 77.3%
* Data from Statistics Finland (Pirkanmaa hospital district, Finland); ** Data from the Finnish Cancer Registry; *** Data from Laboratory of Cancer 
Biology, University of Tampere; **** The trend is statistically significant (P < 0.0001).
NA = not available.Page 2 of 6
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variable. The exponentiated regression coefficient indicates
average change in the proportion of HER-2-positive tumors
per year relative to the first year analyzed. Statistical signifi-
cance was assessed using a likelihood ratio test.
Results
The proportion of breast cancers with HER-2 amplification
was 21.6% in 1982 to 1986, 17.6% in 1989 to 1992, and
13.6% in 2004 to 2005 (Table 2). The tumor samples in the
historical cohorts were selected randomly based on the cases
reported to the Finnish Cancer Registry, and nearly all tumors
(91.8%) were analyzed for the newest cohort (2004 to 2005),
so these figures were used to estimate the incidence trends of
HER-2-positive breast cancer in the population. The epidemi-
ologic data (obtained from the Finnish Cancer Registry)
showed that the annual number of newly diagnosed invasive
breast cancers diagnosed in the Pirkanmaa Hospital District
increased from 191 (average from 1982 to 1986) to 389
(average from 2004 to 2005) during the study period. The
female population had increased only slightly (from 216,000 in
1982 to 1986 to 231,000 in 2004 to 2005). Using these fig-
ures, the average age-adjusted incidence of invasive breast
cancer was found to have increased by 40% (56.3/100,000
in 1982 to 1986, 68.9/100,000 in 1989 to 1992, and 95.3/
100,000 in 2004 to 2005; Tables 1 and 2). These figures are
very close to those reported for the whole country [11].
By multiplying the proportion of HER-2-positive breast cancer
with the overall breast cancer incidence, we estimated that the
age-standardized incidence of HER-2-positive breast cancer
was 12.2/100,000 from 1982 to 1986, 12.1/100,000 from
1989 to 1992, and 13.0/100,000 from 2004 to 2005 (age-
adjusted to WHO standard population; Table 2, 3rd column).
In contrast, when multiplying the incidence of breast cancer
with the proportion of HER-2-negative tumors (78.4%, 82.4%,
and 86.4%, respectively), we found that the incidence of HER-
2-negative cancer had almost doubled (from 44.1/100,000 to
82.3/100,000 women; Table 2). The rates are graphically pre-
sented in Figure 1. The Poisson regression analysis indicated
a 2% annual increase in HER-2-negative cancer (incidence
rate ratio = 1.021, 95% confidence interval (CI) = 1.016 to
1.026). For HER-2-positive cancer there was no trend (inci-
dence rate ratio = 1.000, 95% CI = 0.989 to 1.012). Adjust-
ing the results according to the age of the patients assayed for
HER-2 did not affect the results.
The results of the most recent cohort were further analyzed for
the possible effect of early diagnostics. We found that 33.4%
of all invasive tumors were detected by screening mammogra-
phy among the screened age groups (Table 3). Tumors that
were HER-2 positive, estrogen receptor and progestrone
receptor negative, or triple-negative were statistifically signifi-
cantly underrepresented in patients whose cancers were
detected by mammography screening (P = 0.039, P <
0.0001, P < 0.0001, and P = 0.100, respectively; Table 3).
Discussion
Our results indicate that the commonly used phrase '20% to
30% of breast cancers show HER-2 oncogene amplification'
does not appear to be valid in a well-defined population-based
cohort of Finnish breast cancer patients diagnosed in recent
years. In our patient population, less than 15% of breast can-
cers showed amplification of the HER-2 oncogene. Thus,
there is an apparent discrepancy with earlier literature [6], for
which we sought to find an explanation by analyzing tumors
from our archives retrospectively using the current CISH
method. Comparison of the historical and more recent cohorts
indicated that the proportion of HER-2-positive invasive breast
cancer has clearly declined. The proportion found in the oldest
cohort (1982 to 1986) was in good agreement with that
reported in the literature, including a study from the same pop-
ulation [9], although our previous study was based on detec-
tion of HER-2 protein overexpression by
immunohistochemistry instead of gene amplification [9].
As in most western countries, the age-adjusted incidence of all
breast cancers had increased during the study period. In the
Pirkanmaa Hospital District the increase in age-adjusted inci-
dence was estimated to be 40%. Thus, we were able to disen-
tangle the two opposing trends, that is, the decrease of the
proportion of HER-2-positive breast cancer and increase in
Table 2
Trends in the incidence and proportion of HER-2-positive breast cancer from 1982 to 2005 in the Pirkanmaa Hospital District
Breast cancer cohort Mean annual age-
adjusted incidence*
(per 100,000)
Proportion of HER-2-
positive breast cancers
Estimated age-adjusted 
incidence of HER-2-positive 
breast cancer
(per 100,000)**
Estimated age-adjusted 
incidence of HER-2-
negative breast cancer
(per 100,000)**
1982 to 1986 56.3 21.6% (67/310) 12.2 44.1
1989 to 1992 68.9 17.6% (19/108) 12.1 56.8
2004 to 2005 95.3 13.6% (97/713) 13.0 82.3
* Data from the Finnish Cancer Registry, age-adjusted to the world standard population; ** Estimated by multiplying the incidence of all breast 
cancers and the proportion of HER-2 positive.
HER-2 = human epidermal growth factor receptor 2.Page 3 of 6
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two trends were found to balance out each other. Our data
indicated that the incidence of HER-2-positive breast cancer
in the female population had remained stable. The increased
incidence of breast cancer seemed to be due to HER-2-nega-
tive disease. To the best of our knowledge incidence trends in
HER-2-negative and HER-2-positive breast cancers have not
been reported in the literature.
Only relatively few studies have examined epidemiologic time
trends of biologic subtypes of breast cancer. An increase in
the incidence of hormone receptor-positive breast cancer has
been documented [15-17]. As HER-2 and hormone receptors
are inversely associated (e.g. P < 0.0001 in reference [6]; the
p-value was calculated for our results in this study and the
same phenomenon has been shown also in the reference 6),
these observations are in line with our results of decreased
incidence HER-2. Similar to the published reports, we also
found a significant increase in the proportion of estrogen
receptor-positive tumors in this study (from 59.4% in 1982 to
1986 to 89.8% in 2004 to 2005; Table 1). However, the data
may be biased, because the estrogen receptor assay method
had changed (ligand-binding assay was used in 1982 to
1986; immunohistochemistry on frozen sections in 1989 to
1992; immunohistochemistry on paraffin sections in 2004 to
2005). The sensitivity of these assay methods may differ and
the possible bias is impossible to determine retrospectively.
In addition to hormone receptor data, changes in breast can-
cer histopathology has also been documented in the literature
[18,19]. Increasing incidence of invasive lobular carcinoma
[18,19] is in line with the decrease of HER-2-positive breast
cancers, because these two features are inversely correlated
[20,21]. Thus, based on the literature, the decreased propor-
tion of HER-2-positive breast cancer may at least partly be
explained by the increase of hormone receptor-positive and
lobular carcinoma, which are mostly HER-2 negative.
Given the fact that the incidence of different subtypes of
breast cancer really is changing, this suggests that the known
risk factors of breast cancer do not affect all subtypes equally.
As the incidence of HER-2-positive breast cancer was found
Figure 1
Time trends of age-adjusted breast cancer incidence and proportion of HER-2-positive bre st cancer in the Pirkanmaan Hospital district from 1982 to 2005
HER-2-positive breast cancer in the Pirkanmaan Hospital district from 
1982 to 2005. Bullets = overall breast cancer incidence; rings = esti-
mated incidence of human epidermal growth factor receptor 2 (HER-
2)-negative breast cancer; closed squares = estimated incidence of 
HER-2-positive breast cancer; open squares = proportion of HER-2-
positive breast cancer.
Table 3
Characteristics of breast cancers diagnosed from 2004 to 2005 by the method of detection (screening vs. clinical)
Proportion detected by screening mammography (%) P value
All patients * 196/587 (33.4%) -
HER-2 negative 180/516 (34.9%)
HER-2 positive 16/71 (22.5%) 0.039
ER positive 191/536 (35.6%)
ER negative 5/51 (9.8%) < 0.0001
PR positive 171/460 (37.2%)
PR negative 25/102 (19.7%) < 0.0001
Triple negative 4/32 (12.5%)
Non-triple negative 192/555 (34.6%) 0.100
* Patients over 50 years old (age group of screening). ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; PR = 
progesterone receptor.Page 4 of 6
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ative risk factors, which remain unknown, have probably
remained unchanged. On the other hand, our results suggest
that the impact of the risk factors for HER-2-negative cancer
may have increased. One such risk factor could be menopau-
sal hormone replacement therapy (HRT), which is a well-
defined risk factor for breast cancer in general [22,23]. The
use of HRT increased in Finland five-fold in the period from
1980 to 2000 [24], although a slight decrease occurred after
2003 [25]. However, the decrease in HRT use in Finland has
been much smaller than in many other countries [25].
Several studies have demonstrated that the breast cancers in
women who have used HRT are more frequently estrogen
receptor and progesterone receptor positive than in those
who have not used HRT [26,27]. Because it is well known that
HER-2 amplification is inversely associated with hormone
receptor positivity [6], it is possible that use of HRT may be
associated with a risk of HER-2-negative disease. This theory
is also supported by the association between HRT and
increased incidence of invasive lobular breast carcinoma
[28,29].
One possible explanation for the observed time trends is that
intensified screening for breast cancer may detect a larger
proportion of slowly growing HER-2-negative tumors with a
longer lead-time than other tumor types. In line with previous
studies that have characterized biomarker profiles of screen-
detected breast cancers [30], our results demonstrated that
HER-2-positive tumors are underrepresented in the screen-
detected patient group, similar to that of tumors characterized
by negative hormone receptor status or with a lack of all three
markers (triple negative). In our study, screening is likely to
give a partial explanation to the shift in biomarker profiles.
Nationwide screening mammography was not in practice dur-
ing the first period of the study (1982 to 1986), but was intro-
duced gradually in 1989 to 1992; in 2004 to 2005 almost
90% of all women aged between 50 and 69 years participated
in bi-annual mammography screening [31]. In the newest
cohort (age group 50+ years) with clinically detected disease,
the proportion of HER-2-positive disease (12.8%) was much
lower than in early cohorts in 1982 to 1986 (19.1%, patients
over 50 years old). This suggests that screening bias is a less
important factor to explain the decrease seen in the proportion
of HER-2-positive disease.
Conclusions
These results document a significant decrease in the propor-
tion of HER-2-positive breast cancer in an epidemiologically
defined patient cohort during 1982 to 2005. At the same time,
the overall incidence of breast cancer showed an increase of
40%. The estimated incidence of HER-2-positive cancer at the
population level was found to be stable.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
KK and JI were responsible for data collection, analysis, man-
uscript preparation, and editing. MT participated in data col-
lection and designing of the study. AA contributed to study
design, and planned and performed the statistical analysis. All
authors read and approved the final manuscript.
Acknowledgements
The authors wish to thank Professor Risto Sankila (Finnish Cancer Reg-
istry, Helsinki, Finland) for providing epidemiologic data of breast cancer 
in the Pirkanmaa Hospital district, Dr Paula Kujala for providing clinical 
data and Sari Toivola for technical assistance. Financial support was 
from the Academy of Finland, the Finnish Cancer Foundation, the Finn-
ish Medical Foundation, Juselius Foundation, and the Scientific Founda-
tion of the Pirkanmaa Hospital District.
References
1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire
WL: Human breast cancer: correlation of relapse and survival
with amplification of the HER-2/neu oncogene.  Science 1987,
235:177-182.
2. Demonty G, Bernard-Marty C, Puglisi F, Mancini I, Piccart M:
Progress and new standards of care in the management of
HER-2 positive breast cancer.  Eur J Cancer 2007, 43:497-509.
3. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson
NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisan-
sky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yoth-
ers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle
WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant
chemotherapy for operable HER2-positive breast cancer.  N
Engl J Med 2005, 353:1673-1684.
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A,
Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron
D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M,
Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohr-
isch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C,
Straehle C, McFadden E, Dolci MS, Gelber RD, Herceptin Adju-
vant (HERA) Trial Study Team: Trastuzumab after adjuvant
chemotherapy in HER2-positive breast cancer.  N Engl J Med
2005, 353:1659-1672.
5. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M,
Pawlicki M, Chan A, Smylie M, Liu M, Falkson C, Pinter T, Forn-
ander T, Shiftan T, Valero V, von Minckwitz G, Mackey J, Tabah-
Fisch I, Buyse M, Lindsay MA, Riva A, Bee V, Pegram M, Press M,
Crown J: BCIRG 006: 2nd interim analysis phase III rand-
omized trial comparing doxorubicin and cyclophosphamide
followed by docetaxel (AC T) with doxorubicin and cyclophos-
phamide followed by docetaxel and trastuzumab (AC TH) with
docetaxel, carboplatin and trastuzumab (TCH) in Her2neu
positive early breast cancer patients [abstract].  Breast Cancer
Res Treat 2006, 100(Suppl 1):52.
6. Cardoso F, Durbecq V, Sotiriou C, Ross JS: HER-2/neu gene and
protein in breast cancer.  In Molecular oncology of breast cancer
Edited by: Ross J, Hortobagyi G. Boston: Jones and Bartlett;
2005:232-255. 
7. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT,
Feuer EJ, Edwards BK, Berry DA: The decrease in breast-cancer
incidence in 2003 in the United States.  N Engl J Med 2007,
356:1670-1674.
8. Sant M, Francisci S, Capocaccia R, Verdecchia A, Allemani C,
Berrino F: Time trends of breast cancer survival in Europe in
relation to incidence and mortality.  Int J Cancer 2006,
119:2417-2422.
9. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ:
Association of c-erbB-2 protein over-expression with high rate
of cell proliferation, increased risk of visceral metastasis andPage 5 of 6
(page number not for citation purposes)
Breast Cancer Research    Vol 11 No 3    Köninki et al.poor long-term survival in breast cancer.  Int J Cancer 1991,
49:650-655.
10. Toikkanen S, Helin H, Isola J, Joensuu H: Prognostic significance
of HER-2 oncoprotein expression in breast cancer: a 30-year
follow-up.  J Clin Oncol 1992, 10:1044-1048.
11. Finnish Cancer Registry: Cancer statistics   [http://www.cancer
registry.fi/eng/statistics/]
12. Teppo L, Pukkala E, Lehtonen M: Data quality and quality control
of a population-based cancer registry. Experience in Finland.
Acta Oncol 1994, 33:365-369.
13. Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM:
Interlaboratory comparison of HER-2 oncogene amplification
as detected by chromogenic and fluorescence in situ hybridi-
zation.  Clin Cancer Res 2004, 10:4793-4798.
14. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V,
Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeen-
niemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johans-
son K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J,
Salminen T, Leinonen M, Elomaa I, Isola J, FinHer Study Investiga-
tors: Adjuvant docetaxel or vinorelbine with or without trastu-
zumab for breast cancer.  N Engl J Med 2006, 354:809-820.
15. Glass AG, Hoover RN: Rising incidence of breast cancer: rela-
tionship to stage and receptor status.  J Natl Cancer Inst 1990,
82:693-696.
16. Pujol P, Hilsenbeck SG, Chamness GC, Elledge RM: Rising lev-
els of estrogen receptor in breast cancer over 2 decades.  Can-
cer 1994, 74:1523-1524.
17. Li CI, Daling JR, Malone KE: Incidence of invasive breast cancer
by hormone receptor status from 1992 to 1998.  J Clin Oncol
2003, 21:28-34.
18. Zhao H, Langerod A, Ji Y, Nowels KW, Nesland JM, Tibshirani R,
Bukholm IK, Kåresen R, Botstein D, Børresen-Dale AL, Jeffrey SS:
Different gene expression patterns in invasive lobular and
ductal carcinomas of the breast.  Mol Biol Cell 2004,
15:2523-2536.
19. Cocquyt V, Van Belle S: Lobular carcinoma in situ and invasive
lobular cancer of the breast.  Curr Opin Obstet Gynecol 2005,
17:55-60.
20. Hoff ER, Tubbs RR, Myles JL, Procop GW: HER2/neu amplifica-
tion in breast cancer: stratification by tumor type and grade.
Am J Clin Pathol 2002, 117:916-921.
21. Bane AL, Tjan S, Parkes RK, Andrulis I, O'Malley FP: Invasive lob-
ular carcinoma: to grade or not to grade.  Mod Pathol 2005,
18:621-628.
22. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg
C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson
KC, Kotchen JM, Ockene J, Writing Group for the Women's Health
Initiative Investigators: Risks and benefits of estrogen plus pro-
gestin in healthy postmenopausal women: principal results
From the Women's Health Initiative randomized controlled
trial.  JAMA 2002, 288:321-333.
23. Beral V, Banks E, Reeves G: Evidence from randomised trials
on the long-term effects of hormone replacement therapy.
Lancet 2002, 360:942-944.
24. Hemminki E, Karttunen T, Hovi SL, Karro H: The drug industry
and medical practice – the case of menopausal hormone ther-
apy in Estonia.  Soc Sci Med 2004, 58:89-97.
25. Hemminki E, Kyyrönen P, Pukkala E: Postmenopausal hormone
drugs and breast and colon cancer: Nordic countries 1995–
2005.  Maturitas 2008, 61:299-304.
26. Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD,
Colditz GA: Association of hormone replacement therapy to
estrogen and progesterone receptor status in invasive breast
carcinoma.  Cancer 2004, 101:1490-1500.
27. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE:
Risk factors for breast cancer according to estrogen and pro-
gesterone receptor status.  J Natl Cancer Inst 2004,
96:218-228.
28. Manjer J, Malina J, Berglund G, Bondeson L, Garne JP, Janzon L:
Increased incidence of small and well-differentiated breast
tumours in post-menopausal women following hormone-
replacement therapy.  Int J Cancer 2001, 92:919-922.
29. Reeves GK, Beral V, Green J, Gathani T, Bull D, Million Women
Study Collaborators: Hormonal therapy for menopause and
breast-cancer risk by histological type: a cohort study and
meta-analysis.  Lancet Oncol 2006, 7:910-918.
30. Sihto H, Lundin J, Lehtimäki T, Sarlomo-Rikala M, Bützow R, Holli
K, Sailas L, Kataja V, Lundin M, Turpeenniemi-Hujanen T, Isola J,
Heikkilä P, Joensuu H: Molecular subtypes of breast cancers
detected in mammography screening and outside of screen-
ing.  Clin Cancer Res 2008, 14:4103-4110.
31. Statistics of mass screening activities   [http://www.cancerreg
istry.fi/eng/statistics/]Page 6 of 6
(page number not for citation purposes)
